A Smits1, J McGrane2, A Lopes1, E Kent1, R Bekkers3, L Massuger3, N Simpson4, K Galaal1. 1. Gynae-oncology Surgical Team, Royal Cornwall Hospital, Truro, UK. 2. Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK. john.mcgrane@nhs.net. 3. Obstetrics and Gynaecology, Radboud UMC, Nijmegen, The Netherlands. 4. Sunrise Oncology Centre, Royal Cornwall Hospital, Truro, UK.
Abstract
OBJECTIVE: To assess the impact of body mass index (BMI) on radiotherapy toxicities in endometrial cancer patients. METHODS: This was a retrospective cohort study of women diagnosed with endometrial cancer between January 2006 and December 2014 at the Royal Cornwall Hospital Trust. Women who received radiotherapy as part of their treatment, including external beam radiotherapy (EBRT) and/or vaginal brachytherapy were included. Radiation-related toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) guidelines. Toxicity outcomes were compared across BMI groups-non-obese (BMI <30 kg/m2) and obese (BMI ≥30 kg/m2)-according to radiotherapy treatment received (EBRT, brachytherapy or a combination). RESULTS: Of a total of 159 women who received radiotherapy, 110 were eligible for inclusion in the study. Sixty-three women had a BMI <30 kg/m2 and 47 women were obese. Obese women had poorer Eastern Cooperative Oncology Group performance status (P = 0.021) and more comorbidities (P < 0.001) compared to the non-obese group. Total (any) toxicity rates were 60.3, 72.7 and 52.0% for EBRT and brachytherapy (N = 63), single-mode EBRT (N = 22) and brachytherapy (N = 25), respectively. BMI was not associated with the incidence of acute and late radiation toxicities in the different radiotherapy groups, and there were no differences in individual complications between the BMI groups. CONCLUSION: When comparing obese to non-obese women, obesity does not negatively impact the incidence of radiation toxicities in endometrial cancer. However, toxicities remain an important challenge as they are common and negatively influence the quality of life (QoL) of survivors. Future studies need to further explore the role of BMI and possible interventions to improve toxicities and QoL.
OBJECTIVE: To assess the impact of body mass index (BMI) on radiotherapy toxicities in endometrial cancerpatients. METHODS: This was a retrospective cohort study of women diagnosed with endometrial cancer between January 2006 and December 2014 at the Royal Cornwall Hospital Trust. Women who received radiotherapy as part of their treatment, including external beam radiotherapy (EBRT) and/or vaginal brachytherapy were included. Radiation-related toxicities were graded according to the Radiation Therapy Oncology Group (RTOG) guidelines. Toxicity outcomes were compared across BMI groups-non-obese (BMI <30 kg/m2) and obese (BMI ≥30 kg/m2)-according to radiotherapy treatment received (EBRT, brachytherapy or a combination). RESULTS: Of a total of 159 women who received radiotherapy, 110 were eligible for inclusion in the study. Sixty-three women had a BMI <30 kg/m2 and 47 women were obese. Obesewomen had poorer Eastern Cooperative Oncology Group performance status (P = 0.021) and more comorbidities (P < 0.001) compared to the non-obese group. Total (any) toxicity rates were 60.3, 72.7 and 52.0% for EBRT and brachytherapy (N = 63), single-mode EBRT (N = 22) and brachytherapy (N = 25), respectively. BMI was not associated with the incidence of acute and late radiation toxicities in the different radiotherapy groups, and there were no differences in individual complications between the BMI groups. CONCLUSION: When comparing obese to non-obesewomen, obesity does not negatively impact the incidence of radiation toxicities in endometrial cancer. However, toxicities remain an important challenge as they are common and negatively influence the quality of life (QoL) of survivors. Future studies need to further explore the role of BMI and possible interventions to improve toxicities and QoL.
Authors: R A Nout; V T H B M Smit; H Putter; I M Jürgenliemk-Schulz; J J Jobsen; L C H W Lutgens; E M van der Steen-Banasik; J W M Mens; A Slot; M C Stenfert Kroese; B N F M van Bunningen; A C Ansink; W L J van Putten; C L Creutzberg Journal: Lancet Date: 2010-03-06 Impact factor: 79.321
Authors: Arno J Mundt; Anthony E Lujan; Jacob Rotmensch; Steven E Waggoner; S Diane Yamada; Gini Fleming; John C Roeske Journal: Int J Radiat Oncol Biol Phys Date: 2002-04-01 Impact factor: 7.038
Authors: Vivian E von Gruenigen; Chunqiao Tian; Heidi Frasure; Steven Waggoner; Henry Keys; Richard R Barakat Journal: Cancer Date: 2006-12-15 Impact factor: 6.860
Authors: Brendan Whelan; Shivani Kumar; Jason Dowling; Jarrad Begg; Jonathan Lambert; Karen Lim; Shalini K Vinod; Peter B Greer; Lois Holloway Journal: Australas Phys Eng Sci Med Date: 2015-09-04 Impact factor: 1.430
Authors: P Blake; Ann Marie Swart; J Orton; H Kitchener; T Whelan; H Lukka; E Eisenhauer; M Bacon; D Tu; M K B Parmar; C Amos; C Murray; W Qian Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: Jessica D Arden; Jonathan Dokter; Muayad F Almahariq; Kimberly Marvin; Sirisha R Nandalur; Zaid Al-Wahab; Jill Gadzinski; Barry Rosen; Maha Saada Jawad Journal: Adv Radiat Oncol Date: 2021-08-12